Pfizer, Moderna test vaccine strategies against new COVID-19 variants

first_imgAdvertisementTags: ModernaPfizerVaccinevariants Moderna files for authorization of COVID vaccine in teens ages 12-17 June 11, 2021 Pfizer and Moderna are trying to get out ahead of some of the new COVID-19 variants that are causing concern.Although there’s currently no evidence to suggest people who have been vaccinated with either shot have less protection against the variants, both Pfizer and Moderna said they have started researching ways to account for evolving mutations, reported CNN.The B. 1. 351 variant first seen in South Africa carries a mutation that helps it elude the body’s immune response to infection.The B.1.1.7 variant first seen in the UK carries a mutation that appears to make it more transmissible, meaning it spreads more easily, and it may also cause more severe disease. Half of Americans now fully vaccinated against COVID-19 May 26, 2021 AdvertisementDC Young Fly knocks out heckler (video) – Rolling OutRead more6 comments’Mortal Kombat’ Exceeded Expectations Says WarnerMedia ExecutiveRead more2 commentsDo You Remember Bob’s Big Boy?Read more1 commentsKISS Front Man Paul Stanley Reveals This Is The End Of KISS As A Touring Band, For RealRead more1 comments Moderna trial showing promise for expanding age requirement next month May 26, 2021 Advertisement RELATEDTOPICS AdvertisementAccording to CNN, researchers are also finding variants across the United States that have developed mutations that help them evade the immune system.Pfizer and its partner, BioNTech, said on Thursday that they have started testing how well adding a third dose of their authorized vaccine might protect against the new variants.Pfizer’s study will look at the safety and immune response of a booster dose in up to 144 participants from their earlier Phase 1 trial in the US, including a subset of older adults up to the age of 85. Moderna asking for full FDA approval of its COVID vaccine June 2, 2021 Advertisement AdvertisementRecommended ArticlesBrie Larson Reportedly Replacing Robert Downey Jr. As The Face Of The MCURead more81 commentsGal Gadot Reportedly Being Recast As Wonder Woman For The FlashRead more29 comments The study will also test how well participants’ antibodies are able to neutralize “strains of interest” in the lab, Pfizer and BioNTech said.Volunteers for the study would receive a third dose of the vaccine between 6 and 12 months after their previous two doses. The dosage would be identical to what’s currently authorized — 30 micrograms.“This booster study is critical to understanding the safety of a third dose and efficacy against circulating strains,” Pfizer CEO Dr. Albert Bourla said in a statement.Pfizer and BioNTech are also “in ongoing discussions with regulatory authorities” about possibly testing a vaccine that would be modified to protect against variants in a Phase 1/2 study. Bourla noted that they have not yet seen compelling evidence that variants are resistant to its vaccine, though they are taking steps to be prepared, reported CNN.Moderna announced late Wednesday that it has produced an updated version of its vaccine to help combat the B. 1. 351 variant. Initial doses have already been shipped to the National Institutes of Health for a clinical study, reported CNN.Moderna’s new vaccine will be evaluated as a booster shot for people who have already been vaccinated against COVID-19 and as a primary vaccine for those have not yet been vaccinated and have not had coronavirus.The vaccine maker said it will also evaluate a “multivalent” booster shot that combines the new vaccine formulation with the current vaccine.Additionally, the company said it has begun to test whether a third, lower dose of its current Covid-19 vaccine can increase immunity against coronavirus variants of concern, with some study participants already getting third doses.“We are moving quickly to test updates to the vaccines that address emerging variants of the virus in the clinic. Moderna is committed to making as many updates to our vaccine as necessary until the pandemic is under control. We hope to demonstrate that booster doses, if necessary, can be done at lower dose levels, which will allow us to provide many more doses to the global community in late 2021 and 2022 if necessary,” Stephane Bancel, Moderna’s CEO, said in a statement.The company did not say how long it expects the studies to take or when the new vaccine would be available. The Food and Drug Administration announced new guidelines on Monday that would streamline and speed the process of updating vaccines to target variants.“It’s going to be on the order of a few hundred individuals in terms of size and we’d expect that that might take a few months,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said during a call with reporters on Monday.Both Moderna’s and Pfizer’s vaccine use a new technology using messenger RNA or mRNA that simply requires a genetic code. The design is meant to make the vaccines easy to update quickly, without the months of preparation needed to change an influenza vaccine, for example.The-CNN-Wire™ & © 2021 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.last_img

Leave a Reply

Your email address will not be published. Required fields are marked *